TRIANA Biomedicines
Matt Harlow is a highly skilled scientist with extensive experience in oncology and cancer biology. Currently serving as a Senior Scientist at TRIANA Biomedicines since February 2024, Matt has previously held positions as Scientist II at Civetta Therapeutics from October 2021 to September 2023 and as a Postdoctoral Fellow at Dana-Farber Cancer Institute from September 2017 to October 2021. Educationally, Matt earned a PhD in Oncology and Cancer Biology from Vanderbilt University School of Medicine, where studies were completed from 2011 to 2017, following a Bachelor of Science degree in Biology from the University of North Carolina at Chapel Hill from 2005 to 2009.
This person is not in any teams
This person is not in any offices
TRIANA Biomedicines
Triana Biomedicines is a developer of a molecular glue discovery platform to regulate disease targets that are difficult to address with any other modality. Triana’s drug discovery engine is powered by high-resolution structural insights, state-of-the-art in silico tools, and bespoke chemical libraries. The research team has validated thebest-in-class platform and initiated multiple programs across different disease areas.